Foghorn Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$111M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Foghorn Therapeutics's estimated annual revenue is currently $22.9M per year.(i)
  • Foghorn Therapeutics received $50.0M in venture funding in March 2018.
  • Foghorn Therapeutics's estimated revenue per employee is $126,740
  • Foghorn Therapeutics's total funding is $111M.

Employee Data

  • Foghorn Therapeutics has 181 Employees.(i)
  • Foghorn Therapeutics grew their employee count by 29% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M1-99%N/AN/A
#2
$3.1M20233%N/AN/A
#3
$21.5M13918%$351MN/A
#4
$18M1165%$312.8MN/A
#5
$235M418-23%$340.9MN/A
#6
$2.2M3417%N/AN/A
#7
$6M40-9%$176.5MN/A
#8
$1.8M28367%N/AN/A
#9
$109.4M70614%N/AN/A
#10
$6.2M40233%N/AN/A

More than 20,000 genes make us human. Genes control critical aspects of health and disease but what controls our genes A Flagship Pioneering company, Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control(TM) platform, Foghorn will change how genes turn on and off. Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for usand rewrite destiny for millions of people living with disease. With Gene Traffic Control(TM) Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.

keywords:N/A

$111M

Total Funding

181

Number of Employees

$22.9M

Revenue (est)

29%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Foghorn Therapeutics News

2022-04-17 - Foghorn Therapeutics Presents New Preclinical Data on ...

Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the...

2022-04-17 - Foghorn Therapeutics Presents New Preclinical Data on ...

About Foghorn Therapeutics Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined...

2022-04-06 - Foghorn Therapeutics to Present Preclinical Data For FHD ...

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and...

2019-09-08 - Cigall Kadoch Unravels Chromatin’s Role in Cancer

Over the past few years, she has turned down money from pharmaceutical companies so that she could cofound Foghorn Therapeutics, hoping ...

2019-05-12 - Foghorn Therapeutics takes aim at chromatin hijackers to stop ...

A decade ago, when Cigall Kadoch joined Gerald Crabtree's lab at Stanford University, she was an odd fit: the incoming graduate student was ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$53.8M181101%N/A
#2
$15M18230%$2.2B
#3
$28.4M182-18%$19.5M
#4
$36M1826%N/A
#5
$4.5M1845%$173.3M

Foghorn Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-03-14$50.0MUndisclosedFlagship PioneeringArticle